Patent Grant
12127912
Some embodiments of the present disclosure relate to a wound dressing and a method of treatment. In particular, but not exclusively, the present disclosure relates to an apparatus and method for providing protection at a wound site, for absorbing wound exudate, and providing a number of benefits to both users and those around them over known techniques.
Patients have to live with chronic or acute wounds for durations ranging from a number of days to a number of years. Their quality of life is unavoidably affected, and even more so if the impact of the wound on patients' daily activities cannot be minimised by the dressing chosen.
Patients often report fear of the dressing leaking, of odour from the wound incommoding their relatives, or of the dressing becoming unsightly as it is being used. As patients move, the dressing may be submitted to stretching and/or bending of the skin, or rubbing from clothes or bed linen. While modern dressings are designed to stretch to some extent, lifting of the dressing borders during everyday activities does occur, and reinforces concerns about leakage and odour. The corresponding worry about stigma, and cleanliness, can limit a patient's activities in a way that is not beneficial to their overall healing.
In addition, when patients are mobile, fear of damaging their wound further through painful knocks is also present.
The every-day life of patients with a wound can be seen as a balance of risks and benefits. The decisions taken by patients can sometimes go against the prescribed treatment or behaviour recommended by clinicians. Addressing some of the patients' concerns about the state of their dressing while they are wearing it could help to steer patient decisions towards concording with the clinician's recommendations.
In summary, the above-mentioned problems have heretofore been approached in the following ways:
Prevention of leaks: wound dressing have resorted to the use of superabsorbers in their construction to try to limit leakage of wound exudates out of the dressing pad. EP1156838 describes a wound dressing which combines a foam layer and an absorbent layer in intimate contact with the foam, and capable of draining the foam. EP0758219 describes a method for producing such an article.
Odour: several odour control dressings exist, including either activated charcoal layers (Carboflex®, Askina Carbosorb®, Sorbsan plus Carbon®, Carbonet®, Lyofoam C®) or cyclodextrins embedded into a hydrocolloid (ExuDerm Odorshield®, Avery Dennison). Where activated charcoal is used, it is most often placed behind a barrier layer, the intent of which is to keep the charcoal as dry as possible to enable it to trap odours. U.S. Pat. No. 6,348,423 describes an odour-control absorbent dressing, which contains a barrier layer between the wound side of the pad and its odour layer. GB2420286 describes the use of activated charcoal to control wound odour. WO0209782 describes the use of cyclodextrins incorporated into a non-adhering wound dressing. No adhering absorbent dressing also containing a means of controlling odour is currently available on the market.
Conformability and movement: some dressings have been designed to be more conformable to the body than a standard square shape. This is the case for example of dressings design especially for the heel area, or for the sacrum area. WO2008/149107 describes a sacrum dressing with preferential folding lines. In such dressings, both the border and the pad of the dressing can be shaped in relationship to the particular area of the body targeted. WO2004/047695 describes a dressing with indentation in its pad in a honeycomb pattern. Further related patent applications describe other beneficial formats of indentations. An existing product, Comfeel Plus® by Coloplast, has a shaped border which is claimed to increase adhesion and conformability. Furthermore, EP0902672 describes a conformable dressing which has a permanent set after application.
Appearance and cleanliness do not seem to be addressed by existing product offerings, or to have been considered an issue for the patient in the published literature.
Protection from shocks and pressure relief: This problem seems to have been tackled in the industry in the light of preventing pressure ulcers from developing or worsening. It is generally accepted that structures containing air bubbles or gel parts will be able to absorb some of the energy put into compressing a dressing, until the force applied leads to the collapse of the dressing thickness. Foam dressings have therefore been used as part of a pressure relief protocol in clinical settings, but in conjunction with other methods.
WO2007/075379 describes a bi-component dressing, where a first part is formed as a wall around the circumference of the wound, and a second, flatter part, is placed on top of the wall. Pressure applied over a wider area than that delimited by the wall, such as under a compression bandage, would be mostly taken up by the shield structure.
WO2006/091735 and US2009/0069737 describe a similar concept, where a layer of material is punctured. EP1164995 builds on this idea, where a pressure-relieving structure surrounds an absorbent part of the dressing, and is in contact with the skin.
WO2011/144888 describes the use of a three-dimensional knit within a dressing.
The inventors have not found a structure described that meets more than one of the patient needs outlined above. However, patient satisfaction with a particular treatment, and therefore the likelihood that they will comply with it, depends on several clinical and social factors.
According to a first aspect of the present disclosure, there is provided a wound dressing for providing protection at a wound site, comprising:
According to a second aspect of the present disclosure, there is provided a method of manufacturing a wound dressing, comprising:
According to a third aspect of the present disclosure, there is provided a wound dressing for providing protection at a wound site, comprising:
According to a fourth aspect of the present disclosure, there is provided a method of manufacturing a wound dressing, comprising:
According to a fifth aspect of the present disclosure, there is provided a wound dressing for providing protection at a wound site, comprising:
According to a sixth aspect of the present disclosure, there is provided a method of manufacturing a wound dressing, comprising
According to a seventh aspect of the present disclosure, there is provided a wound dressing, comprising:
According to an eighth aspect of the present disclosure, there is provided a method of manufacturing a wound dressing, comprising providing an absorbent layer for absorbing wound exudate;
According to a ninth aspect of the present disclosure, there is provided a wound dressing, comprising: an odour control material and at least one of a foam, an absorbent layer and a shielding layer, wherein the odour control material is incorporated into the at least one other material.
According to a tenth aspect of the present disclosure, there is provided a method of manufacturing a wound dressing, comprising providing an odour control material and at least one of a foam, an absorbent layer and a shielding layer, wherein the odour control material is incorporated into the at least one other material.
According to an eleventh aspect of the present disclosure, there is provided a wound dressing, comprising:
According to a twelfth aspect of the present disclosure, there is provided a method of manufacturing a wound dressing comprising
Certain embodiments of the present disclosure provide the advantage that a wound dressing is provided that has a reduced aesthetic impact for users (compared to known dressings) yet allows clinicians to examine and visually assess the wound area, such as assessing presence of blood, infection by-products and/or the extent of exudate spread across the dressing.
Certain embodiments of the present disclosure provide the advantage that a wound dressing is provided that has improved conformability to an area of a patient to which it is attached, particularly for areas that are not flat/planar.
Certain embodiments of the present disclosure provide the advantage that a wound dressing is provided that has improved performance in terms of protecting a user from shocks or pressure.
Certain embodiments of the present disclosure provide the advantage that odour from a wound is controlled.
Some embodiments provide the advantage that the wound dressing can be used to collect wound exudate generated during a negative pressure therapy process. A pump remote from the wound dressing or supported thereby can be connected to the wound dressing and reused (or can be disposable) whilst the wound dressing itself is used to collect wound exudate and may then be disposed of after use. The pump or other source of negative pressure can be connected to the wound dressing through a flexible tubing or conduit. In this arrangement, negative pressure can draw wound exudate and other fluids or secretions away from the wound site.
Any of the embodiments disclosed herein are suitable for use with and, hence, can be used with a negative pressure wound therapy system to aid in wound closure and healing in which wound exudate drawn from a wound site during the therapy is collected and stored in a wound dressing and/or in a collection canister.
Certain embodiments provide the advantage that a wound dressing of any of the embodiments disclosed herein or having any of the components or features of any wound dressing embodiment disclosed herein can be used to collect wound exudate generated during a negative pressure therapy process, whilst extending the useful lifetime of the dressing by transpiring a water component of the wound exudate. A pump remote from the wound dressing can be connected to the wound dressing and reused whilst the wound dressing itself is used to collect wound exudate and may then be disposed of after use. Embodiments of the present disclosure are further described hereinafter with reference to the accompanying drawings, in which:
In the drawings like reference numerals refer to like parts.
Throughout this specification reference is made to a wound. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, incisions, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. The wound dressing may be used for a human or other living being.
In some embodiments, it may be preferable for the wound site to be filled partially or completely with a wound packing material. This wound packing material is optional, but may be desirable in certain wounds, for example deeper wounds. The wound packing material can be used in addition to the wound dressing. The wound packing material generally may comprise a porous and conformable material, for example foam (including reticulated foams), gauze or a hydrofibre ribbon. Preferably, the wound packing material is sized or shaped to fit within the wound site so as to fill any empty spaces. The wound dressing may then be placed over the wound site and wound packing material overlying the wound site. As used herein the term ‘exudate’ is used to broadly cover any of wound exudate (such as cells, infection by products, cellular debris, proteins, etc.), blood or any other matter released from a wound.
As an overview, the present disclosure relates to an absorbent dressing, where the particular layers provide individual properties to the dressing, and where the combination of these layers in a particular order provides additional properties.
Below are described several properties of such a multi-layered dressing, which can be incorporated independently or in combination with each other.
(a) Dressing pad assembly with layers arranged so that odour control is placed between two layers of different rates of absorptions. This forces the fluid through the odour control layer, but ensures it does not remain saturated with fluid, which enables it to remain efficient.
Odour control can also be achieved by incorporating odour-control materials within some of the other layers of the pad.
Differential absorption also helps to limit the risk of maceration close to the skin, as the foam layer (closest to the wound) is drained of its excess fluid by the superabsorber layer (on the other side of the odour control layer). The superabsorber layer does not allow fluid to be released in liquid form under compression, and fluid can only leave this layer by evaporation, or wicking transfer to a further layer. The superabsorber layer can be shaped to a larger size than the lowest pad layer, to ensure adequate protection against potential leaks by providing a highly absorbent zone at the very edge of the pad. This can also be achieved by including a ring of highly absorbent material superimposed on the pad assembly.
(b) Dressing containing a means of partially obscuring the top surface. The effect is to reduce the visibility of unsightly exudates while allowing clinical judgment on the state of the dressing. This is currently achieved by using a visual masking layer, where overlapping fabrics with openings are disposed slightly offset of each other, for example. While this method allows fluid to wick up through this layer and reach the top film, coloured solids remain onto the layer below, thus containing the coloured solid matter at a little distance from the top film and providing a reduced aesthetics impact.
(c) A dressing design that has enhanced compatibility with body movement by means of:
These can be used individually or in combination of any number, however the effect is maximised by using all options in one embodiment.
(d) A dressing pad design that provides enhanced protection against mechanical forces, both from the outside (shocks, knocks, shear) and the inside (pressure onto wounds from bony protrusions).
Protection against the ill effects of direct pressure can be achieved by incorporating, in the structure of the dressing, a means of spreading a point pressure into a proportionally lower pressure across a larger surface area.
In particular, the use of three-dimensional knits, such as spacer fabrics, can provide the desired effect. The vertical filaments bonding two horizontal knitted layers can help to initially resist collapse of the dressing structure, and spreading of the pressure across a wider area than that of the point force applied. The yield point at which the dressing collapses completely can therefore be seen at higher forces than what traditional foam dressings can withstand.
Pressure distribution maps can also show that such a 3-D structure can spread a point force to a wider area than a foam layer of the same thickness can.
Protection against shear can be achieved by ensuring that the components of the dressing can themselves shear compared to each other: this can diminish what shear forces are being transmitted through to the skin or the wound.
(e) A dressing pad assembly where the following properties are being provided by given material layers, and where the respective position of these layers provides additional properties on top of those from the individual layers. The description below describes the pad composition from the side closest to the wound (i) to the side furthest from the wound (v):
i. Initial fluid uptake into the dressing pad, through a wound contact layer, via a soft, hydrophilic polyurethane foam layer (reduced risk of maceration, comfort, maintain moist wound healing environment)
ii. Odour-control of the fluid taken up via a layer of activated charcoal cloth, which performs in a wet state (odour control)
iii. Transfer of fluid through this odour-control layer and onto an absorbent layer, which does not release the fluid back out in liquid form (reduced risk of maceration, maintain moist wound healing environment)
iv. Impact and shear protection through a three-dimensional knitted fabric, which offers resistance to pressure transfer onto the wound (shock and knock protection)
v. Partial masking of the uppermost surface of the pad through a semi-opaque component (enhanced aesthetic appearance during wear, allowing clinical judgement)
Combination of (ii) and (iii) enhances the odour control capability, as this helps to reduce the fluid saturation of the odour control layer and maximise its efficacy.
Combination of (iii), (iv) and (v) to ensure that fluid is being evaporated from the superabsorber layer, out of the dressing through the moisture-vapour permeable top film.
For all the dressing pads described (a) to (e), the pad is contained between a wound contact layer and a top film.
The wound contact layer can comprise a perforated wound-side adhesive which can be a silicone adhesive, or a low-tack adhesive to minimise skin trauma on removal. The wound contact layer comprises a support material which can be a mesh, a net or a perforated film. It can also comprise a construction adhesive on the pad side, to ensure its intimate contact with the lowest part of the pad, and therefore efficient uptake of fluid from the wound without pooling.
The top film is a liquid-impermeable, moisture-vapour permeable, breathable film, which allows moisture to evaporate from the dressing.
a and 2b respectively show a schematic cross-sectional view, a plan view and a perspective view of a wound dressing according to an embodiment of the present disclosure. The wound dressing 100 includes a number of layers that are built up in a generally laminar fashion to form a dressing having a relatively planar form. The wound dressing 100 includes a border region 110 extending around the outer periphery of the dressing and a raised central region 112 in the centre of the dressing (in plan view). The precise dimensions of the border region and the central region may be predetermined to suit a particular wound or particular wound type. There may be no border region required. Here the border region has the general function of providing an area for sealingly engaging with a patient's skin surrounding a wound site to form a sealed cavity over the wound site. The central region is the location of further functional elements of the wound dressing.
The dressing 100 includes a perforated wound contact layer (101) and a top film (102).
Further components of the wound dressing 100 include:
In this embodiment the wound contact layer 101 is a perforated polyurethane film that is coated with a skin-compatible adhesive, such as pressure sensitive acrylic adhesive or silicone adhesive (not shown). Alternatively the wound contact layer may be formed from any suitable polymer, e.g. silicone, ethylvinyl acetate, polyethylene, polypropylene, or polyester, or a combination thereof. The skin-compatible adhesive is coated on the lower side of the layer 101, i.e. the side that is to contact the patient. Aptly the adhesive is coated as a continuous layer on the underside of the layer 101. Optionally the adhesive may be coated in a semi-continuous layer such as in a pattern such as a chequerboard pattern, polka dot pattern, herring bone pattern, mesh pattern or other suitable pattern. Alternatively the adhesive may be coated around a border region 110 of the dressing only, and not in a central region 112 of the dressing (as viewed from above in plan view) such that the adhesive may adhere to skin surrounding a wound and not the wound itself. The perforations allow the wound contact layer to be permeable to liquid and gas. The perforations are through holes extending from an upper surface to a lower surface of the wound contact layer to enable fluid to flow through the layer. The perforations are small enough to help prevent tissue ingrowth into the wound dressing yet still allow fluid to flow. The perforations may be slits or holes having a size range of 0.025 mm to 1.2 mm for example. The upper surface of layer 101 may optionally be coated with adhesive, to help in the construction of the dressing. Aptly the adhesive may be a pressure sensitive adhesive and aptly the same adhesive as used on the lower surface of the layer 101.
The absorbent layer 103 of polyurethane hydrocellular foam is located over the wound contact layer 101 and extends over the central region 112 of the wound contact layer.
The term hydrocellular is a term given to foams that are absorbent, hydrophilic and polymeric. The foams may have a particular range of cell size of 30 microns to 700 microns.
The foam is in this case of polyurethane, hydrophilic, conformable, resilient, and porous and allows fluids such as wound exudate to be drawn away from the wound site and further into the dressing. However, the foam also maintains a sufficiently moist wound healing environment so as to not dry out the wound, retaining a balanced moist atmosphere under the dressing. An optimal wound healing environment generally requires the area of the wound to have some level of moisture yet without excessive fluid.
The absorbent employed in the absorbent layer of the dressings may be any suitable polymer foam. The foam is aptly a highly conformable hydrophilic foam, aptly an open celled foam, and more aptly the foam is a mixture of open and closed cells.
The absorbent layer used in dressings of the present disclosure is capable of absorbing wound exudate. It is desirable that the foam layer absorbs the wound exudate rapidly. Such rapid absorption prevents undesirable pooling of exudate between the dressing and the wound.
The ability of polymer foam layers to absorb and retain fluids depends to some extent on the size of the foam cells, the porosity of the foam and the thickness of the foam layer. Suitable open cell foams of dressing embodiments of the present disclosure have a cell size of 30 microns to 700 microns and aptly a cell size of 50 microns to 500 microns. Apt open cell hydrophilic foams of dressings of the present disclosure have 20% to 70% and preferably 30% to 60% of the total membrane area of the cells as membrane openings. Such open cell foams permit transport of fluid and cellular debris into and within the foam.
Apt foams may be polyurethane, carboxylated butadiene styrene rubber, polyacrylate or the like foam. Such foams may be made of hydrophilic materials per se or may be treated to render them hydrophilic, for example with surfactants. It is preferred to use foams that are made of polymer that is itself hydrophilic as it has been found the exudate is less likely to coagulate rapidly. Favoured hydrophilic polymer foams are hydrophilic polyurethane and especially those which are made of crosslinked hydrophilic polyurethane. Preferred foams can be made by reacting a hydrophilic isocyanate terminated polyether prepolymer with water. Suitable hydrophilic polyurethane foams of this type include those known as Hypol™ foams. Hypol™ foams can be made from Hypol hydrophilic prepolymers marketed by W. R. Grace and Co and are hydrophilic cellular foams having a mixture of open and closed cells. Hypol™ based foams are also available from Dow Chemicals. Other suitable foams are described in WO91/01706 in relation to the absorbent layer described, incorporated herein by reference, and in WO93/04101 also incorporated herein by reference.
The use of such foams of hydrophilic polymer in the absorbent pad of dressings of the present disclosure can allow the wound to be maintained in a moist condition even when the exudate produced has been absorbed and removed from the wound surface.
A further function of the foam layer is to wick away excess fluid from the wound area via its open cells. It is noted that PU foam itself can absorb liquid, the whole polymer swelling.
The odour-removing layer of activated charcoal cloth 104 is provided over the layer of foam 103. In this embodiment the activated charcoal layer is about the same length and depth as the foam layer and therefore lies over the foam layer to cover about the same area. The layer may be of Zorflex® cloth available from Chemviron Carbon, for example. Alternative suitable materials are manufactured by MAST under the trade name C-TeX®.
The function of the odour-removing layer is to help prevent or reduce odour originating from the wound from transmitting out of the dressing.
It is noted that in this example the odour-removing layer is provided as a loose layer, unbonded to the adjacent layers, though alternatively the layers may be bonded by adhesive or stitching, etc.
The layer of absorbent material 105 is provided over the odour-removing layer 104. The absorbent layer 105 extends fully over the layer 104, as well as over the side portions of both the odour-removing layer 104 and foam layer 103. The absorbent material may be a foam, woven or non-woven or knitted natural or synthetic material and may optionally include or be super-absorbent material. A suitable material may be an air-laid material containing cellulose fibres and superabsorbent polyacrylate particulates or fibres, for example superabsorber cores available from Novathin. Alternatively the absorbent layer 105 may be manufactured from ALLEVYN™ foam, Freudenberg 114-224-4, Chem-Posite™ 11C-450, CMC (e.g. Medline Maxsorb with Alginate), alginate (e.g. ActivHeal Alginate by Advanced Medical Solutions) and/or polyacrylate fibres (e.g. SAF™ by Technical Absorbent Ltd).
The layer 105 forms a reservoir for fluid, particularly liquid, removed from the wound site and draws those fluids towards a cover layer 102. The material of the absorbent layer also prevents liquid collected in the wound dressing from flowing freely once in the dressing structure. The absorbent layer 105 also helps distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer, i.e. transferring and locking in the liquid. This prevents agglomeration in areas of the absorbent layer. The capacity of the absorbent material should be sufficient to manage the exudate flow rate of a wound for the predetermined life of the dressing, whether the wound is acute or chronic. Again, in combination with the foam layer, the layer 105 aptly should not cause the wound to become completely dry. This might occur if, for example, the superabsorbent material were to dry out the foam layer and then subsequently the wound area.
Aptly, the absorbent layer is a layer of non-woven cellulose fibres having super-absorbent material in the form of dry particles dispersed throughout. Use of the cellulose fibres introduces fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibres leads to strong capillary action in the fibrous pad which helps distribute liquid. In this way, the super-absorbent material is efficiently supplied with liquid. Also, all regions of the absorbent layer are provided with liquid.
The absorbent layer 105 aptly has a high osmotic potential so as to prevent liquid being released from the layer, even when the layer is under compression (e.g. if the dressing area is pressed or leant on). Liquid may however leave the layer by diffusion through evaporation or possibly wicking transfer to a further layer.
The layer of absorbent material 105 may be of any suitable dimensions. Aptly, if the layer is shaped to a size larger than the layers between itself and the wound contact layer, then the layer can fold over the edges of any intermediate layers, acting as an enclosure such that any fluid moving into the dressing will encounter the absorbent layer prior to encountering the top film or the adhesive wound contact layer. This helps to prevent possible leaks of fluid from the dressing. As an alternative, a ring shaped (annular or torus) or other suitable border shaped portion of absorbent material may be added to a dressing separately from the absorbent layer to surround underlying layers and to perform the same function as the overlying edge of the absorbent layer.
Optionally, according to certain embodiments of the present disclosure, the absorbent layer may include synthetic staple fibres and/or bi-component staple fibres and/or natural staple fibres and/or super-absorbent fibres. Fibres in the absorbent layer may be secured together by latex bonding or thermal bonding or hydrogen bonding or a combination of any bonding technique or other securing mechanism. Aptly, the absorbent layer is formed by fibres which operate to lock super-absorbent particles within the absorbent layer. This helps ensure that super-absorbent particles do not move external to the absorbent layer and towards an underlying wound bed.
Aptly, the fibres are strand-like and made from cellulose, polyester, viscose or the like. Aptly, dry absorbent particles are distributed throughout the absorbent layer ready for use. Aptly, the absorbent layer comprises a pad of cellulose fibres and a plurality of super absorbent particles. Aptly, the absorbent layer is a non-woven layer of randomly orientated cellulose fibres.
Super-absorber particles/fibres may be, for example, sodium polyacrylate or carbomethoxycellulose materials or the like or any material capable of absorbing many times its own weight in liquid. Aptly, the material can absorb more than five times its own weight of 0.9% W/W saline, etc. Aptly, the material can absorb more than 15 times its own weight of 0.9% W/W saline, etc. Aptly, the material is capable of absorbing more than 20 times its own weight of 0.9% W/W saline, etc. Aptly, the material is capable of absorbing more than 30 times its own weight of 0.9% W/W saline, etc.
Aptly, the particles of superabsorber are very hydrophilic and grab the fluid as it enters the layer, swelling up on contact. An equilibrium is set up within the dressing core whereby moisture passes from the superabsorber to the top film and the fluid vapour starts to be transpired. A moisture gradient may be established within the dressing to continually remove fluid from the wound bed.
The shielding layer 106 is a layer having a 3-dimensional structure that may include open cell foam (e.g. Alleyvn™ foam by Smith & Nephew, Biatain foam by Coloplast or Advanced Medical Devices' ActivHeal foam), a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester or Baltex XD spacer fabric or Surgical Mesh's Polyester felt or Polyester mesh) or a non-woven fabric (e.g. Fiberweb's S-tex or Securon). Alternatively the shielding layer may be a completely opaque polymer film having cut-out windows or perforations, for example (e.g. SNEF's H514 or H518 blue net). Here the layer 106 is of polyester that includes a top layer (that is, a layer distal from the wound in use), which is a 84/144 textured polyester, a bottom layer (that is, a layer that lies proximate to the wound in use), which is a 100 denier flat polyester and a third layer formed sandwiched between these two layers, which is a region defined by a knitted polyester viscose, cellulose or the like monofilament fibre. Of course other materials and other linear mass densities of fibre could be used, including for example a multistrand alternative. The shielding layer 106 may be similar or identical to the materials described in US2011/0282309 in relation to the transmission layer (FIGS. 23 to 27).
The layer 106 allows the transmission therethrough of any gas or vapour to the top film 102 and may therefore be considered as a transmission layer.
Aptly the layer 106 performs one or more further functions including acting as a partial masking layer and acting as a force distributing (impact protection) layer.
Partial masking of wound exudate, blood or other matter released from a wound may be achieved with overlapping perforated fabrics disposed somewhat offset from each other, such as shown in
Alternatively, as shown in
More specifically, it is known that when a film is breathable (able to transmit vapour), then it is likely to allow colour to transmit therethrough. Even if a breathable film includes a coloured pigment for masking a lower layer, when exudate fluid contacts the film, coloured elements in the exudate can be carried into contact with the film and change the colour perception from the film, and be visible to the user. This allows fluid to transmit through the layer towards the top film whilst coloured solids or liquids remain bound in the absorbent layer below. Exudate colour is principally due to proteins and biological break down products from tissue or blood cells, which tend to be large molecules.
Another function of the shielding layer 106 may be for pressure distribution and impact protection. For example, if the patient accidentally knocks the wound area, leans on the wound area or another cause applies a pressure to the dressing covering a wound. Aptly the shielding layer is provided closer to where the pressure is being applied than other layers of the dressing.
The shielding layer 106 acts as a pressure spreading component, receiving a pressure on one side thereof (possibly a point force) and spreading the pressure over a wider area, thus reducing the relative pressure received on the other side of the shielding layer. As such, the level of pressure felt by the patient at the wound site is reduced.
A form of shielding layer that has been found to be a good pressure distributed is a layer having non-ordered fibres or strands, i.e. fibres lying at different angles with respect to each other, for example the knitted spacer fabric of Baltex 7970.
The absorbent layer 105 may also act as a pressure spreading component. A combination of the shielding layer 106 and the absorbent layer 105 has been found to give particularly apt pressure distributing properties. However, only one pressure spreading component may be sufficient.
In general, a material that is relatively non-deformable is more suitable for spreading point pressure. However this should be balanced by the requirement for deformation ability for the dressing to adhere to a non-planar body part.
When a pressure occurs from inside the patient's body, such as pressure from a protruding bone, the shielding layer may be somewhat less efficient at spreading the pressure if it is positioned towards the distal part of the dressing. However, any equal and opposite reaction of force acting back toward the patient's skin will be spread by the shielding layer 106 and absorbent layer 105 (e.g. if the patient is laying on something hard such as the ground or hard chair). The pressure spreading response will depend somewhat upon the hardness of the surface against which the patient and dressing are pressed against, if any.
The pressure spreading ability of these layers may also be useful against slower, constant pressures as well as rapid point forces.
The top film 102 is a cover layer for covering the lower layers of the dressing, helping to encapsulate the layers between the wound contact layer and the top film. The top film 102 is in this case a layer of polyurethane, Elastollan (trade name) SP9109 manufactured by BASF. The top film may be coated with any suitable adhesive. Aptly the adhesive will be a pressure sensitive adhesive e.g. acrylic adhesive or silicone adhesive.
As such, the top film 102 helps to ensure that the dressing remains breathable, i.e. allows a proportion of fluid absorbed in the dressing to be evaporated via the outer surface of the dressing. In this way certain fluid content of the exudate can be transpired from the dressing, reducing the volume of remaining exudate and increasing the time before the dressing becomes full. Also, the wound contact layer 101 and top cover 102 help to ensure that the border region 110 of the dressing remains breathable, i.e. allows a patient's normal skin perspiration to be evaporated through the dressing, which helps in preventing or minimising skin maceration.
The outer layer of dressings of the present disclosure when present can be a continuous conformable film. The continuous moisture vapour transmitting conformable film outer layer of the wound dressing may be used to regulate the moisture loss from the wound area under the dressing and also to act as a barrier to bacteria so that bacteria on the outside surface of the dressing cannot penetrate to the wound area. Suitable continuous conformable films will have a moisture vapour transmission rate of at least 300, aptly from 300 to 5000 grams preferably 500 to 2000 grams/square meter/24 hrs at 37.5 C at 100% to 10% relative humidity difference. Such moisture vapour transmission rate of the continuous film allows the wound under the dressing to heal under moist conditions without causing the skin surrounding the wound to macerate. To ensure the use of an adhesive on the top film 102 does not reduce the moisture vapour transmission rate, a hydrophilic water dispersible adhesive may be used e.g. hydrophilic acrylic adhesives. Although, other suitable adhesive may also be used. Aptly adhesive may also be spread across the surface of the film in the form of a pattern such that a portion of the area of the film does not contain adhesive. E.g., use of a polka dot pattern whereby adhesive is not present in the dot area and 5 to 95%, or aptly 10 to 80%, more aptly 30 to 70%, more aptly 40 to 70%, more aptly 40 to 60%, more aptly 40 to 50% of the area of film does not contain adhesive. It will be apparent to those skilled in the art that any suitable pattern of adhesive layer may be used to produce a top film 102 that is not fully coated with adhesive and thus maximises the moisture vapour transmission rate. Other suitable materials for the cover layer are described in WO91/01706 in relation to the conformable moisture vapour transmitting outer layer.
Additionally, the top film may act as a further barrier to any remaining odour from being transmitted out of the wound dressing, since the top film may include through holes that allow molecules of a predetermined maximum size to pass therethrough.
Reverting back to
In the border region 110, the top film 102 abuts with the wound contact layer 101. A moisture vapour transmitting adhesive layer is provided (not shown) in the border region 110 between the layers 101, 102 to bond the layers in that region. Suitable adhesives that are moisture vapour transmitting include various acrylate ester copolymer and polyvinyl ether pressure sensitive adhesives for example as described in UK patent number 1280631. Aptly the adhesives may be copolymers of an acrylate ester with acrylic acid for example as described in UK patent application number 2070631.
The dimensions of the components are arranged so as to minimise the angle of incidence of the dressing edge. This helps to reduce rubbing of the dressing against textiles and reduced snagging of the dressing against textile, by reducing the change in profile of the dressing throughout the thickness of the dressing.
In use, a wound dressing as described above would be applied to a wound site of a patient with the surface of the wound contact layer 101 facing the wound site. Any wound exudate, blood or other wound fluid would travel into the dressing via the wound contact layer and sequential layers above the wound contact layer. Fluid would permeate through the foam layer, the activated charcoal layer, and then reach the absorber layer at which point preferably the liquid would not go any further and be retained by the absorber layer. On the other hand, gas and moisture vapour would be able to permeate further via the shielding layer and/or top film.
The wound dressing of the disclosure may be of any suitable shape or form or size. The overall dimensions of the dressing may be, for example, 160 mm diameter, although any total size may be used, and the size may be determined to match particular wound sizes.
In addition, it is noted that the dressing's improved conformability with non-planar (bodily) shapes can be achieved in part by combining a foam with a material that could be only returned to its initial shape by a force higher than that applied onto it by foam. The role of this second material is to remain in the shape it was given at the application of the dressing, despite the forces applied to it by the foam material trying to relax after deformation at application. E.g. airlaid or non woven material with broken or displaced fibres by the initial application force could provide sufficient resistance against pressure of a hydrocellular foam layer (2 to 4 mm).
The inventors have realised that a dressing formed from foam only will tend to revert to its natural position (planar or flat in the case of the foam layers described here). The foam has a ‘memory’ of how it was cut and manufactured. Thus when foam dressings are applied with adhesive onto non-flat body parts the adhesive must be sufficiently strong to oppose the force of the foam reverting to its original shape.
As shown in
That is, sample 6a included a wound contact layer having an adhesive on its ‘wound facing’ side, a foam layer (such as layer 103) and a cover layer (such as top film 102). Sample 6b included a wound contact layer having an adhesive on its ‘wound facing’ side, a foam layer (such as layer 103), an absorbent layer (such as layer 105), a shielding layer (such as layer 106) and a cover layer (such as top film 102).
The initial shapes of the two samples shown in
It is believed that components of the dressing of the disclosure, such as the absorbent layer or shielding layer, can plastically deform without memory, by components within the layers being displaced or broken to some degree. For example, some of the fibres in the shielding layer may be broken (without overall damage to the dressing). This displacement or breakage is long term or permanent. As such the force of the foam layer of the dressing reverting to its original shape is counteracted by the displaced or broken components within other layers. As such, as long as the force of the foam layer is lower than the force of returning the other layers to a planar position, the dressing will retain its formed (non-planar) shape.
It can be seen that not only the conformability of the materials of the dressing, but also the discrete sub-areas of the dressing help to keep the dressing adhered to the uneven surface of the patient.
As shown in
The dressing shape has a rotational symmetry about its centre point (in plan view). In this example the dressing has 4 lobes. The shape of the central region 112 matches the shape of the border region 110 such that the width of the border region is approximately equal around the entire dressing. Aptly the border may be between about 12.5 mm and about 29 mm. More aptly the border is about 25 mm. Of course the border size will depend on the full dimensions of the dressing. Other numbers of lobes may be used such as 3, 5, 6, 7, 8, etc. The isotropic nature of the dressing shape gives the advantage that the user is not required to orientate the dressing in a specific manner before applying the dressing to a wound. The shape also enables the dressing to be adaptable to various parts of the body.
The dressing shape with 4 sub areas (lobes) aptly gives a maximum pad area with respect to the border area, yet has increased flexibility compared to a square dressing.
The inventors also performed tests upon various dressings with respect to the dissipation of force applied to the dressing.
From this it can be concluded that fibrous non-woven materials and 3-D knit materials will help to act against a force applied by dissipating the force and preventing compression of the dressing.
Preferably the dressing area to be tested is of 20 cm2 or more when using a cylindrical probe of 10 mm diameter, to ensure that the probe size is not larger than the test sample and to ensure pressure is redistributed efficiently through the sample.
Aptly the pressure spreading layer increases the area over which pressure is transferred by at least 25% of the initial application area and more aptly by at least 50% of the initial application area.
The inventors have found that a combination of materials may, as a composite, increase the area over which pressure is transferred by at least 50%, aptly at least 100%, more aptly at least 200% of the initial application area. An increase in the area over which pressure is transferred of 200%.
Individual components can also be assessed for pressure redistribution from a static test, where a pressure of 736 mmHg is applied statically to various materials. Values obtained are shown in the table below:
The above-described tests on pressure dissipation suggest that a dressing including a shielding layer such as a 3-D spacer layer and optionally also an absorbent layer give enhanced performance in terms of spreading a pressure applied, and thus should perform better against accidental knocks to the wound site for example, compared to known dressings.
The inventors also performed tests upon various dressings with respect to the masking properties of the dressing. The ability to mask colour may be calculated, for example, by measuring the reduction in absorption of light radiation at particular wavelengths.
The inventors noted that any wound exudate may have dark yellow, red and/or brown tones. Therefore, to appropriately mask these colours, a masking layer would need to shield light wavelengths of below 600 nm.
Measuring the reduction in absorption of light radiation at particular wavelengths may be performed by calculating:
% reduction=(Abackground−Asample placed on background)/(Abackground)×100
where A is the absorption of light radiation at the particular wavelength.
Using this formula, using light at a wavelength of 460 nm, the percentage of absorption reduction was calculated as shown in Table 3 below.
It has been found that materials that reduce light absorption by about 50% or more will provide enough partial or complete masking of wound exudate (as judged by the inventors). Of course a complete masking element wound preferably require a means for a clinician to judge the spread of wound exudate in the dressing below the masking element, e.g. the masking element not completely covering the entire dressing. Alternatively a partial masking element may allow a clinician to judge the spread of exudate in the dressing below without additional means.
It will be understood that the wetting of a masking material (by exudate for example) will also affect the masking performance of the masking element, since hydrophilic materials will allow chromophore-carrying species to travel through them more easily. As such, the absorption reduction rate should also be tested on wet materials.
The inventors also tested the above-mentioned Samples 1, 2 and 3 for their masking properties by measuring CIE L*a*b* values (a known 3-dimensional model for representing colour space). The analysis employed Jasco software using the range 380 to 780 nm, stard observed 2(deg), lightsource D65, colour matching JIS Z8701-1999.
Table 4 below shows the L*a*b* values found when Samples 1, 2 and 3 were respectively placed over a black background. The results for the black background alone and a white background are also shown.
Generally, samples which lead to an increase in L* value will provide a lighter colour tone than the reference surface, which is the main contributor to masking a dark colour. From the values above, apt partial masking materials will yield an L* value above 50, or more aptly above 70.
However, completely opaque masking layers, such as for example a tinted polymeric film, may cover the area to be masked with a darker tone altogether, in which case the measure of L* is not relevant.
Once again these values should also be considered on wet material, for the reasons stated above.
In addition, the dressing of the disclosure may be arranged to prevent shear stress between layers from causing damage to the dressing. This is because the layers are generally not adhered together, other than the top film 102 and wound contact layer 101 being adhered in the border region 110. Thus even if friction or other energy from shear movement occurs, the energy is dissipated by the layers prior to reaching the patient.
The wound facing surface of a wound dressing may be provided with a release coated protector (not shown in the figures), for example a silicon-coated paper. The protector covers the wound contacting side of the dressing prior to application to a patient, and can be peeled away at the time of use.
Various modifications to the detailed arrangements as described above are possible. For example, dressings according to the present disclosure do not require each of the specific layers as described above with respect to
As noted above, each of the layers described may be used to give one or more function to the wound dressing. As such, each of the layer materials may be used separately or in any combination such that each material provides the given function.
The wound contact layer described above is an optional layer. If used, a wound contact layer may be of any suitable material, such as polyethylene (or polyurethane as described above) or other suitable polymer, and may be perforated for example by a hot pin process, laser ablation process, ultrasound process or in some other way so as to be permeable to fluids.
Although the dressing described above has been described having a border region and a central region this need not be the case. The dressing may be provided without an adhesive layer for attachment to the skin of a patient. Rather, another means may be provided for locating the dressing at the correct position over a wound, such as adhesive tape or a tied bandage.
The relative widths of the various layers may be all the same or different to those as shown in the figures.
The dressing pad assembly may optionally be arranged with layers so that odour control is placed between two layers of different rates of absorptions. The odour control layer can be a charcoal cloth (knitted, woven, felt, non-woven), or any other textile, foam, gel, net or mesh impregnated with odour-control materials. Such odour control materials can be cyclodextrins, zeolites, ion-exchange resins, oxidising agents, activated charcoal powder. It is also possible to use said odour-control materials dispersed in any layer of the pad assembly, and not as a discrete layer.
The dressing may optionally include a means of partially obscuring the top surface. This could also be achieved using a textile (knitted, woven, or non-woven) layer without openings, provided it still enables fluid evaporation from the absorbent structure. It could also be achieved by printing a masking pattern on the top film, or on the top surface of the uppermost pad component, using an appropriate ink or coloured pad component (yarn, thread, coating) respectively. Another way of achieving this would be to have a completely opaque top surface, which could be temporarily opened by the clinician for inspection of the dressing state (for example through a window), and closed again without compromising the environment of the wound.
The dressing may optionally be arranged such that it has enhanced compatibility with body movement. This could also be achieved using a different shape for the sub-areas, such as diamonds, triangles, or a plurality of such shapes tessellated across the area of the dressing. Alternatively, preferential folding lines may be scored within the thickness of the dressing material, and thus define independent sub-areas for adapting to movement. Alternatively, the layers could be bonded using an elastic material, such as a viscoelastic adhesive, which would allow shear between the layers but refrain them from becoming separated and shifting across the pad.
A dressing may optionally be arranged that provides enhanced protection against mechanical forces. Other ways of achieving this include:
A dressing assembly may optionally be arranged where the flowing properties are being provided by given material layers, and where the respective position of these layers provides additional properties on top of those from the individual layers. Alternative arrangement of layers than that described above may still provide some of the properties sought.
For example, placing the shielding layer (106) below the superabsorbent layer (105) would still allow protection from point pressure, but would lose the masking ability of this layer, and would probably affect the transmission of fluid between the foam layer (103) and the superabsorbent layer (105).
Another example is the placement of the odour control layer or component further away from the wound: this can be seen as beneficial because some types of odour control work differently depending on whether they are wet or dry. Placing a colour-less odour control component towards the top of the dressing (anywhere above (105)) could provide odour control properties without the visual impact that a black layer of charcoal cloth would have.
It can also be envisaged that several properties are combined within one layer, for example superabsorbent and odour control components could be incorporated in the foam structure. The only remaining optional properties to provide in this case would be protection and masking, which could be achieved by placing a layer (106) directly above such a modified foam if needed.
Interestingly, the fluid handling properties of an embodiment where the superabsorbing function is located within the lowest part of the dressing pad may not be as beneficial as those of an embodiment where the functions are held in separate layers, and the fluid is directed from one layer to another.
In another embodiment, the shielding layer 106 is of the same dimensions as 105, and clinical judgment of the exudate spread can be made by observing the spread of exudate through the masking layer. This embodiment has the advantage of completely masking unsightly exudate from the superabsorbent layer.
Alternatively or additionally, the shielding layer can be provided with full masking capability, and windows provided at discrete points of the layer for enabling judgement of the exudate spread below such layer. Examples of such windows are illustrated in FIGS. 12a and 12b. The dressing 1200 shown in
In another embodiment, odour control is not provided by a separate layer (i.e. no layer 104), but instead the odour-control material (activated charcoal, cyclodextrin, ion exchange resin, or other) is dispersed throughout another layer. This can be envisaged within the foam (103), the superabsorbent structure (105), or as a coating onto the masking layer (106).
In addition or alternatively, the obscuring layer may be coated with or formed from a material with size-exclusion properties to help with masking the exudate from view. For example, such a layer could have its lowermost side (the side closer to the wound) coated with materials such as zeolites or clays such as bentonite or sepiolite (the charged surface of which will tend to attract proteins and protein derivatives containing chromophores), other inorganic powders or molecular sieves (e.g. amberlite), proteins (albumin, haemoglobin components with molecular weight 15 to 70 KDa), ionic complexes such as hemes (molecular weight 600 to 850 g/mol), which have the function of immobilising species above a certain size or molecular weight. For example, species having molecular weight above 100 g/mol.
The shielding layer may be coated with or be formed of a hydrophilic compound (e.g. polyesters, polyurethanes, polyureas, polysaccharides, etc.) for assisting in wicking moisture towards the surface of the dressing, helping breathability of the dressing.
The shielding layer may be combined with a cover layer, such as an opaque or dark pigmented top layer.
The shielding layer (acting as a masking layer) may be combined with an absorbent layer, for example by providing an absorbent layer that has been dyed, for example with a dark blue pigment to the fibres of a non-woven or airlaid material.
The shielding layer (acting as a pressure relieving layer) may be combined with an absorbent layer. For example a fibrous superabsorber layer may be provided with a high density of fibres for spreading point pressure. Alternatively a hydrophilic foam may be moulded around pressure-redistributing structures of pillars or arrays of an elastomer material, for example.
Odour control can be combined with absorbency by dispersing particles of activated charcoal or other odour-catching material in a hydrophilic foam at time of reaction, or dispersing it throughout an air-laid material as a powder, or introducing it in the master batch of absorbent polymer used to manufacture fibres which will then be used in an air-laid.
As such, odour control, absorbency and pressure redistribution could be included in a single layer, and if this material was dyed, masking could also be performed.
The layers described herein may each be provided directly adjacent another layer or with further layers therebetween.
A wound dressing may be formed by bringing together a layer of absorbent material with a layer of obscuring material.
Alternatively a wound dressing may be formed by bringing together a layer of absorbent material with a layer of protective material.
Alternatively a wound dressing may be formed by bringing together a layer of absorbent material with a cover layer.
Alternatively a wound dressing may be formed by bringing together a layer of absorbent material with a fluid transmission layer with a layer of activated charcoal material therebetween.
Any of the methods above may include bringing layers together with adhesive over part or all of a layer. The method may be a lamination process.
Alternatively a wound dressing may be formed by bringing together layers as described with respect to
Alternatively a wound dressing may be formed by forming a sheet of material for absorbing wound exudate, the sheet comprising at least one of a foam, an odour capturing material, an absorbent material, and a shielding material for masking or pressure spreading.
The dressing of the disclosure may be manufactured by continuous production techniques. For example, a sheet or sheets of suitable material may be run through rollers to enable the adhesion of one layer to another. Alternatively, pre-cut pad component shapes can be placed onto a web of one of the adhesive film or net components, before being encapsulated by the another adhesive film or net component. Then the dressing may be stamped out by cutting through the material in the desired shape and packaged.
In use, a wound dressing of the present disclosure would be applied to a wound site of a patient with the surface of the wound contacting side of the dressing facing the wound site. The wound dressing would then be monitored over a predetermined time period to assess the extent of exudate present in the dressing. The dressing may be any of the examples and embodiments described herein.
The dressing may be monitored at predetermined intervals or at predetermined time(s) of the day. For example, the dressing may be monitored every 6 hours, or once every morning, lunchtime and evening, for example, or as required by the specific patient.
A method for determining the saturation of a wound dressing with wound exudate comprises:
The dressing may be any of the dressings described herein.
With the above-described arrangements one or more advantages over known dressings may be achieved.
The disclosure described contains elements which lead to a combination of properties that is not currently being met by existing devices.
In particular, the combination of an effective odour-control layer, held between two absorbent layers of differential absorption power, yields an absorbent structure which does not require a barrier layer to remain efficient against odours.
The odour-removing layer is not bonded to adjacent layers. Because of this, the available surface area of active pores of the odour layer is not diminished. That is, in known dressings including an odour resistant layer of activated charcoal, the material is carbonised to insert carbon into the surface porosity of the layer. The layer is then adhered to an adjacent layer, thus coating some of the porous surface area with adhesive, and reducing the total surface porosity.
The present disclosure comprising a shaped pad and dressing border, working as more independent sub-units of the dressing than what can be seen for a standard square shape, yields better conformability with movement than standard shapes. The dressing remains conformable with the skin and comfortable to wear, allowing the patient to move whilst wearing the dressing, and without creating detrimental traction on the peri-wound skin, which could lead to slowing of wound healing.
Some embodiments of the present disclosure also help to reduce the unsightly appearance of a dressing during use, by using materials that impart partial masking of the dressing surface. The masking should preferably only be partial, to allow clinicians to access the information they require by observing the spread of exudate across the dressing surface. This property, which is very important in helping patients live better with their treatment, had not been achieved until now for absorbent, breathable dressings. The partial masking nature of the obscuring layer enables a skilled clinician to perceive a different colour caused by exudate, blood, by-products etc. in the dressing allowing for a visual assessment and monitoring of the extent of spread across the dressing. However, since the change in colour of the dressing from its clean state to a state with exudate contained is only a slight change, the patient is unlikely to notice any aesthetic difference. Reducing or eliminating a visual indicator of wound exudate from a patient is likely to have a positive effect on their health, reducing stress for example. Also, some embodiments of the present disclosure provide a mean of relieving point pressure that may be applied to the wound area, by introducing a breathable, shear resistant layer that does not have to be in contact with the skin. This construction maximises the absorbency capacity of the dressing by not replacing some of the absorbent area with pressure-relieving areas. Breathability of the part of the dressing in contact with the skin is also maximise, as the breathable wound contact layer, lower part of the pad, and film, are not impaired by the use of another structure in contact with the skin.
By providing an odour control layer between a foam and an absorber layer, this can help in allowing only excess fluid towards the absorber layer, whilst keeping the foam layer sufficiently moist to create a moist wound healing environment. This is because the odour layer does not draw fluid away from the foam layer at the same speed at which an absorbent layer would. The transfer of fluid from the foam layer to the absorbent layer is therefore slowed down (relative to having a foam layer directly adjacent an absorber layer).
Therefore, only excess fluid is taken into the odour layer, thereby assisting in the foam layer maintaining some degree of moisture and not drying out.
That is, the absorption rate of the outer layer should aptly be higher than the absorption rate of the lower layer (closer to the wound).
Prior to the invention of the embodiments disclosed herein, it was generally believed that the wetting of activated charcoal would destroy the function of the material of performing odour capturing. As such, activated charcoal layers have been used as an outer layer protected from liquid by a barrier layer. However the inventors found that as long as the activated charcoal layer is not soaked in liquid the activated charcoal can perform sufficiently well as an odour removing layer.
When the layer of absorbent material folds over the edges of any other lower layers, the absorbent layer helps to prevent fluid from being squeezed from the dressing at the dressing edge region, thereby causing leakage. Various known dressings previously suffered from the risk of delamination of layers caused by fluid being squeezed towards the edge of the dressing, being driven between the layers and possibly escaping at the edge of the dressing. This may occur for example in a border region where a wound contact layer meets a cover layer, and any intermediate layers of the dressing are adjacent that border region. Aptly an absorbent layer including a superabsorber material is useful in preventing the release of any liquid, especially in the direction of the border region or edge of the dressing.
Alternative materials can be used for the absorbent layer to provide the fluid locking and leak prevention properties, for example:
absorbent or superabsorbent gels or solids, which can be hydrocolloid polymer structures, additionally comprising superabsorbent particles or fibres.
Additionally, any of the dressing embodiments disclosed herein can be used in with a source of negative pressure, such as a pump. Any of the dressing embodiments disclosed herein can also be used with a pump and a fluid or waste collection canister that can be put in fluid communication with the pump and the dressing so that the pump draws fluid or waste from the wound into the collection canister.
Additionally, in any embodiments, the pump can be a piezoelectric pump, a diaphragm pump, a voice coil actuated pump, a constant tension spring actuated pump, a manually actuated or operated pump, a battery powered pump, a DC or AC motor actuated pump, a combination of any of the foregoing, or any other suitable pump.
With the some embodiments of the present disclosure, a wound dressing is provided that helps improve patient concordance with instructions for use, helps improve patients” quality of life, and also helps a clinician observe and monitor a patient's wound.
It will be clear to a person skilled in the art that features described in relation to any of the embodiments described above can be applicable interchangeably between the different embodiments. The embodiments described above are examples to illustrate various features of the present invention or inventions.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the present disclosure are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
This application is a continuation of U.S. application Ser. No. 16/195,186, filed on Nov. 19, 2018, which is a continuation of U.S. application Ser. No. 15/219,886, filed on Jul. 26, 2016, which is a continuation of U.S. application Ser. No. 14/232,607, having a 371(c) date of May 21, 2014, which is a U.S. National Phase of the PCT International Application No. PCT/GB2012/000587, filed on Jul. 12, 2012, which claims priority to UK Application Nos. 1112084.7 and 1211171.2, filed on Jul. 14, 2011 and Jun. 22, 2012, respectively; all of which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 730062 | Widmer | Jun 1903 | A |
| 1052274 | Purdy, I | Feb 1913 | A |
| 2054768 | Gale, Jr. et al. | Sep 1936 | A |
| 2233209 | Herzog | Feb 1941 | A |
| 2280506 | Betts | Apr 1942 | A |
| 2682873 | Idnis et al. | Jul 1954 | A |
| 2905174 | Smith | Sep 1959 | A |
| 2992644 | Plantinga et al. | Jul 1961 | A |
| 3043301 | Plantinga et al. | Jul 1962 | A |
| 3156242 | Crowe, Jr. et al. | Nov 1964 | A |
| 3204277 | Sierik et al. | Sep 1965 | A |
| 3301429 | McClain | Jan 1967 | A |
| 3416524 | Meier | Dec 1968 | A |
| 3529597 | Fuzak et al. | Sep 1970 | A |
| 3616154 | Dow et al. | Oct 1971 | A |
| 3687136 | Carmody | Aug 1972 | A |
| 4212296 | Schaar | Jul 1980 | A |
| 4649909 | Thompson | Mar 1987 | A |
| 4798603 | Meyer et al. | Jan 1989 | A |
| 4834735 | Alemany et al. | May 1989 | A |
| 4846164 | Martz | Jul 1989 | A |
| 4901714 | Jensen | Feb 1990 | A |
| 4968181 | Goldman | Nov 1990 | A |
| 4973325 | Sherrod et al. | Nov 1990 | A |
| 4988344 | Reising et al. | Jan 1991 | A |
| 4988345 | Reising | Jan 1991 | A |
| 5018515 | Gilman | May 1991 | A |
| 5021050 | Iskra | Jun 1991 | A |
| 5037409 | Chen et al. | Aug 1991 | A |
| 5065600 | Byles | Nov 1991 | A |
| 5115801 | Cartmell et al. | May 1992 | A |
| 5124197 | Bernardin et al. | Jun 1992 | A |
| 5149334 | Lahrman et al. | Sep 1992 | A |
| 5151091 | Glaug et al. | Sep 1992 | A |
| 5160328 | Cartmell et al. | Nov 1992 | A |
| 5171391 | Chmielewski et al. | Dec 1992 | A |
| 5175046 | Nguyen | Dec 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5197945 | Cole et al. | Mar 1993 | A |
| 5217445 | Young et al. | Jun 1993 | A |
| 5236427 | Hamajima et al. | Aug 1993 | A |
| 5242435 | Murji et al. | Sep 1993 | A |
| 5257982 | Cohen et al. | Nov 1993 | A |
| 5271987 | Iskra | Dec 1993 | A |
| 5281208 | Thompson et al. | Jan 1994 | A |
| 5294478 | Wanek et al. | Mar 1994 | A |
| 5296290 | Brassington | Mar 1994 | A |
| 5314743 | Meirowitz et al. | May 1994 | A |
| 5318554 | Young et al. | Jun 1994 | A |
| 5330456 | Robinson | Jul 1994 | A |
| 5336219 | Krantz | Aug 1994 | A |
| 5342336 | Meirowitz et al. | Aug 1994 | A |
| 5348547 | Payne et al. | Sep 1994 | A |
| 5354261 | Clark et al. | Oct 1994 | A |
| 5356405 | Thompson et al. | Oct 1994 | A |
| 5360420 | Cook et al. | Nov 1994 | A |
| 5364381 | Soga et al. | Nov 1994 | A |
| 5364382 | Latimer et al. | Nov 1994 | A |
| 5366451 | Levesque | Nov 1994 | A |
| 5368909 | Langdon et al. | Nov 1994 | A |
| 5368926 | Thompson et al. | Nov 1994 | A |
| 5374260 | Lemay et al. | Dec 1994 | A |
| 5380294 | Persson | Jan 1995 | A |
| 5382245 | Thompson et al. | Jan 1995 | A |
| 5387208 | Ashton et al. | Feb 1995 | A |
| 5387209 | Yamamoto et al. | Feb 1995 | A |
| 5397316 | LaVon et al. | Mar 1995 | A |
| 5401267 | Couture-Dorschner et al. | Mar 1995 | A |
| 5425725 | Tanzer et al. | Jun 1995 | A |
| 5431643 | Ouellette et al. | Jul 1995 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5447492 | Cartmell et al. | Sep 1995 | A |
| 5454800 | Hirt et al. | Oct 1995 | A |
| 5456660 | Reich et al. | Oct 1995 | A |
| 5465735 | Patel | Nov 1995 | A |
| 5470326 | Dabi et al. | Nov 1995 | A |
| H1511 | Chappell et al. | Dec 1995 | H |
| 5480377 | Cartmell et al. | Jan 1996 | A |
| 5486167 | Dragoo et al. | Jan 1996 | A |
| 5487736 | Van Phan | Jan 1996 | A |
| 5497788 | Inman et al. | Mar 1996 | A |
| 5500270 | Langdon et al. | Mar 1996 | A |
| 5505719 | Cohen et al. | Apr 1996 | A |
| 5509914 | Osborn, III | Apr 1996 | A |
| 5514120 | Johnston et al. | May 1996 | A |
| 5520629 | Heinecke et al. | May 1996 | A |
| 5525407 | Yang | Jun 1996 | A |
| 5536264 | Hsueh et al. | Jul 1996 | A |
| 5538500 | Peterson | Jul 1996 | A |
| 5540922 | Fabo | Jul 1996 | A |
| H1585 | Ahr | Aug 1996 | H |
| 5545155 | Hseih et al. | Aug 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5549589 | Horney et al. | Aug 1996 | A |
| 5562107 | Lavender et al. | Oct 1996 | A |
| 5562646 | Goldman et al. | Oct 1996 | A |
| 5562650 | Everett et al. | Oct 1996 | A |
| 5579765 | Cox et al. | Dec 1996 | A |
| 5591148 | McFall et al. | Jan 1997 | A |
| 5591149 | Cree et al. | Jan 1997 | A |
| 5593395 | Martz | Jan 1997 | A |
| 5603707 | Trombetta et al. | Feb 1997 | A |
| 5603946 | Constantine | Feb 1997 | A |
| 5609588 | DiPalma et al. | Mar 1997 | A |
| 5613960 | Mizutani | Mar 1997 | A |
| 5614283 | Potnis et al. | Mar 1997 | A |
| 5614295 | Quincy, III et al. | Mar 1997 | A |
| 5628736 | Thompson | May 1997 | A |
| 5632731 | Patel | May 1997 | A |
| H1657 | Hammons et al. | Jun 1997 | H |
| 5634915 | Osterdahl | Jun 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637080 | Geng | Jun 1997 | A |
| 5643238 | Baker | Jul 1997 | A |
| 5645081 | Argenta et al. | Jul 1997 | A |
| 5648142 | Phillips | Jul 1997 | A |
| 5649915 | Chauvette et al. | Jul 1997 | A |
| 5649916 | DiPalma et al. | Jul 1997 | A |
| 5662599 | Reich et al. | Sep 1997 | A |
| 5665082 | Boulanger | Sep 1997 | A |
| 5669895 | Murakami et al. | Sep 1997 | A |
| 5675079 | Gilman et al. | Oct 1997 | A |
| 5683354 | Levy | Nov 1997 | A |
| 5700254 | McDowall et al. | Dec 1997 | A |
| 5702356 | Hathman | Dec 1997 | A |
| 5704905 | Jensen et al. | Jan 1998 | A |
| 5713384 | Roach et al. | Feb 1998 | A |
| 5713842 | Kay | Feb 1998 | A |
| 5716703 | Payne | Feb 1998 | A |
| 5728084 | Palumbo et al. | Mar 1998 | A |
| 5728085 | Widlund et al. | Mar 1998 | A |
| 5733273 | Ahr | Mar 1998 | A |
| 5752945 | Mosley et al. | May 1998 | A |
| 5762641 | Bewick-Sonntag et al. | Jun 1998 | A |
| 5788684 | Abuto et al. | Aug 1998 | A |
| 5801107 | Everhart et al. | Sep 1998 | A |
| 5810798 | Finch et al. | Sep 1998 | A |
| 5817081 | LaVon et al. | Oct 1998 | A |
| 5820578 | Johansen | Oct 1998 | A |
| 5827213 | Jensen | Oct 1998 | A |
| 5827254 | Trombetta et al. | Oct 1998 | A |
| 5830202 | Bogdanski et al. | Nov 1998 | A |
| 5837627 | Halabisky et al. | Nov 1998 | A |
| 5840052 | Johns | Nov 1998 | A |
| 5843025 | Shaari | Dec 1998 | A |
| 5843064 | Koczab | Dec 1998 | A |
| 5855572 | Schmidt | Jan 1999 | A |
| 5865822 | Hamajima et al. | Feb 1999 | A |
| 5865824 | Chen et al. | Feb 1999 | A |
| 5873867 | Coles et al. | Feb 1999 | A |
| 5877097 | West et al. | Mar 1999 | A |
| 5891120 | Chmielewski | Apr 1999 | A |
| 5895379 | Litchholt et al. | Apr 1999 | A |
| 5897541 | Uitenbroek et al. | Apr 1999 | A |
| 5916507 | Dabi et al. | Jun 1999 | A |
| 5925026 | Arteman et al. | Jul 1999 | A |
| 5931823 | Stokes et al. | Aug 1999 | A |
| 5938995 | Koltisko, Jr. et al. | Aug 1999 | A |
| 5941863 | Guidotti et al. | Aug 1999 | A |
| 5947945 | Cree et al. | Sep 1999 | A |
| 5951535 | Fujiwara et al. | Sep 1999 | A |
| 5961506 | Guidotti et al. | Oct 1999 | A |
| 5968027 | Cole et al. | Oct 1999 | A |
| 5989478 | Ouellette et al. | Nov 1999 | A |
| 6022610 | Phan et al. | Feb 2000 | A |
| 6037518 | Guidotti et al. | Mar 2000 | A |
| 6040493 | Cooke et al. | Mar 2000 | A |
| 6060638 | Paul et al. | May 2000 | A |
| 6068620 | Chmielewski | May 2000 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6075177 | Bahia et al. | Jun 2000 | A |
| 6077526 | Scully et al. | Jun 2000 | A |
| 6096015 | Yeo et al. | Aug 2000 | A |
| 6103953 | Cree et al. | Aug 2000 | A |
| 6103954 | Grondin et al. | Aug 2000 | A |
| 6107539 | Palumbo et al. | Aug 2000 | A |
| 6117523 | Sugahara | Sep 2000 | A |
| 6124520 | Roberts | Sep 2000 | A |
| 6124521 | Roberts | Sep 2000 | A |
| 6127595 | Makoui et al. | Oct 2000 | A |
| 6142982 | Hunt et al. | Nov 2000 | A |
| 6168849 | Braverman et al. | Jan 2001 | B1 |
| 6191340 | Carlucci et al. | Feb 2001 | B1 |
| 6206865 | Chen et al. | Mar 2001 | B1 |
| 6223383 | Vanputten | May 2001 | B1 |
| 6235966 | Magnusson et al. | May 2001 | B1 |
| 6264776 | DiPalma | Jul 2001 | B1 |
| 6294710 | Schmidt et al. | Sep 2001 | B1 |
| 6297423 | Schoenfeldt et al. | Oct 2001 | B1 |
| 6344036 | Ivansson | Feb 2002 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6348423 | Griffiths et al. | Feb 2002 | B1 |
| 6362390 | Carlucci et al. | Mar 2002 | B1 |
| 6369292 | Strack et al. | Apr 2002 | B1 |
| 6372952 | Lash et al. | Apr 2002 | B1 |
| 6403857 | Gross et al. | Jun 2002 | B1 |
| 6461339 | Sugahara | Oct 2002 | B1 |
| 6468295 | Augustine et al. | Oct 2002 | B2 |
| 6497689 | Schmidt et al. | Dec 2002 | B1 |
| 6506175 | Goldstein | Jan 2003 | B1 |
| 6506960 | Young et al. | Jan 2003 | B1 |
| 6521813 | Chihani | Feb 2003 | B1 |
| 6528696 | Ireland | Mar 2003 | B1 |
| 6534149 | Daley et al. | Mar 2003 | B1 |
| 6545194 | Schmidt et al. | Apr 2003 | B1 |
| 6551295 | Schmidt et al. | Apr 2003 | B1 |
| 6552244 | Jacques et al. | Apr 2003 | B1 |
| 6570057 | Schmidt et al. | May 2003 | B1 |
| 6570058 | Fuchs et al. | May 2003 | B1 |
| 6573424 | Raidel et al. | Jun 2003 | B1 |
| 6586653 | Graeme, III et al. | Jul 2003 | B2 |
| 6610898 | Magnusson et al. | Aug 2003 | B1 |
| 6610903 | Latimer et al. | Aug 2003 | B1 |
| 6613028 | Daley et al. | Sep 2003 | B1 |
| 6613953 | Altura | Sep 2003 | B1 |
| 6613955 | Lindsay et al. | Sep 2003 | B1 |
| 6626891 | Ohmstede | Sep 2003 | B2 |
| 6630611 | Malowaniec | Oct 2003 | B1 |
| 6648862 | Watson | Nov 2003 | B2 |
| 6664439 | Arndt et al. | Dec 2003 | B1 |
| 6683229 | Ehrnsperger et al. | Jan 2004 | B1 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6706940 | Worthley | Mar 2004 | B2 |
| 6719742 | McCormack et al. | Apr 2004 | B1 |
| 6727403 | Ehrnsperger et al. | Apr 2004 | B1 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6762337 | Boukanov et al. | Jul 2004 | B2 |
| 6764459 | Donaldson | Jul 2004 | B1 |
| 6776769 | Smith | Aug 2004 | B2 |
| 6783837 | Creagan et al. | Aug 2004 | B1 |
| 6787682 | Gilman | Sep 2004 | B2 |
| 6835192 | Guidotti et al. | Dec 2004 | B1 |
| 6838589 | Liedtke et al. | Jan 2005 | B2 |
| 6841715 | Roberts | Jan 2005 | B2 |
| 6878647 | Rezai et al. | Apr 2005 | B1 |
| 6936037 | Bubb et al. | Aug 2005 | B2 |
| 6951553 | Bubb et al. | Oct 2005 | B2 |
| 6960181 | Stevens | Nov 2005 | B2 |
| 6998511 | Worthley | Feb 2006 | B2 |
| 7004915 | Boynton et al. | Feb 2006 | B2 |
| 7049478 | Smith | May 2006 | B1 |
| 7108683 | Zamierowski | Sep 2006 | B2 |
| 7112712 | Ancell | Sep 2006 | B1 |
| 7118545 | Boyde | Oct 2006 | B2 |
| 7122023 | Hinoki | Oct 2006 | B1 |
| 7122712 | Lutri et al. | Oct 2006 | B2 |
| 7183345 | Kim | Feb 2007 | B2 |
| 7195624 | Lockwood et al. | Mar 2007 | B2 |
| 7294751 | Propp et al. | Nov 2007 | B2 |
| 7294752 | Propp | Nov 2007 | B1 |
| 7338482 | Lockwood et al. | Mar 2008 | B2 |
| 7381859 | Hunt et al. | Jun 2008 | B2 |
| 7429689 | Chen et al. | Sep 2008 | B2 |
| 7438705 | Karpowicz et al. | Oct 2008 | B2 |
| 7476205 | Erdmann | Jan 2009 | B2 |
| 7507870 | Nielsen et al. | Mar 2009 | B2 |
| 7511187 | Kelly | Mar 2009 | B2 |
| 7563940 | Kurata | Jul 2009 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7576256 | Bjornberg et al. | Aug 2009 | B2 |
| 7605298 | Bechert et al. | Oct 2009 | B2 |
| 7615036 | Joshi et al. | Nov 2009 | B2 |
| 7622629 | Aali | Nov 2009 | B2 |
| 7645269 | Zamierowski | Jan 2010 | B2 |
| 7676257 | Suryanarayanan et al. | Mar 2010 | B2 |
| 7708724 | Weston | May 2010 | B2 |
| 7722582 | Lina et al. | May 2010 | B2 |
| 7723561 | Propp | May 2010 | B2 |
| 7749531 | Booher | Jul 2010 | B2 |
| 7759537 | Bishop et al. | Jul 2010 | B2 |
| 7759539 | Shaw et al. | Jul 2010 | B2 |
| 7775998 | Riesinger | Aug 2010 | B2 |
| 7776028 | Miller et al. | Aug 2010 | B2 |
| 7779625 | Joshi et al. | Aug 2010 | B2 |
| 7794438 | Henley et al. | Sep 2010 | B2 |
| 7838719 | Hilton, Jr. | Nov 2010 | B2 |
| 7838723 | Schmidt et al. | Nov 2010 | B1 |
| 7909805 | Weston | Mar 2011 | B2 |
| 7922703 | Riesinger | Apr 2011 | B2 |
| 7935066 | Shives et al. | May 2011 | B2 |
| 7959624 | Riesinger | Jun 2011 | B2 |
| 7964766 | Blott et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7985209 | Villanueva et al. | Jul 2011 | B2 |
| 7988673 | Wright et al. | Aug 2011 | B2 |
| 8021347 | Vitaris et al. | Sep 2011 | B2 |
| 8062272 | Weston | Nov 2011 | B2 |
| 8092436 | Christensen | Jan 2012 | B2 |
| 8147468 | Barta et al. | Apr 2012 | B2 |
| 8152785 | Vitaris | Apr 2012 | B2 |
| 8162907 | Heagle | Apr 2012 | B2 |
| 8168848 | Lockwood et al. | May 2012 | B2 |
| 8188331 | Barta et al. | May 2012 | B2 |
| 8202261 | Kazala, Jr. et al. | Jun 2012 | B2 |
| 8212101 | Propp | Jul 2012 | B2 |
| 8241261 | Randolph et al. | Aug 2012 | B2 |
| 8246606 | Stevenson et al. | Aug 2012 | B2 |
| 8252971 | Aali et al. | Aug 2012 | B2 |
| 8314283 | Kingsford et al. | Nov 2012 | B2 |
| 8328858 | Barsky et al. | Dec 2012 | B2 |
| 8372050 | Jaeb et al. | Feb 2013 | B2 |
| 8376972 | Fleischmann | Feb 2013 | B2 |
| 8382731 | Johannison | Feb 2013 | B2 |
| 8403899 | Sherman | Mar 2013 | B2 |
| 8404921 | Lee et al. | Mar 2013 | B2 |
| 8425478 | Olson | Apr 2013 | B2 |
| 8444611 | Wilkes et al. | May 2013 | B2 |
| 8449508 | Coulthard et al. | May 2013 | B2 |
| 8481804 | Timothy | Jul 2013 | B2 |
| 8513481 | Gergely et al. | Aug 2013 | B2 |
| 8535296 | Blott et al. | Sep 2013 | B2 |
| 8545466 | Andresen et al. | Oct 2013 | B2 |
| 8663198 | Buan et al. | Mar 2014 | B2 |
| 8680360 | Greener et al. | Mar 2014 | B2 |
| 8708998 | Weston et al. | Apr 2014 | B2 |
| 8715256 | Greener | May 2014 | B2 |
| 8722961 | Vinton et al. | May 2014 | B2 |
| 8764732 | Hartwell | Jul 2014 | B2 |
| 8791316 | Greener | Jul 2014 | B2 |
| 8795247 | Bennett et al. | Aug 2014 | B2 |
| 8801685 | Armstrong et al. | Aug 2014 | B2 |
| 8814842 | Coulthard et al. | Aug 2014 | B2 |
| 8829263 | Haggstrom et al. | Sep 2014 | B2 |
| 8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
| 8916742 | Smith | Dec 2014 | B2 |
| 8986270 | Johannison et al. | Mar 2015 | B2 |
| 9012714 | Fleischmann | Apr 2015 | B2 |
| 9033942 | Vess | May 2015 | B2 |
| 9061095 | Adie et al. | Jun 2015 | B2 |
| 9220822 | Hartwell | Dec 2015 | B2 |
| 9254353 | Locke et al. | Feb 2016 | B2 |
| 9265665 | Robinson et al. | Feb 2016 | B2 |
| 9579411 | Addison et al. | Feb 2017 | B2 |
| 10080689 | Hall et al. | Sep 2018 | B2 |
| 10537657 | Phillips et al. | Jan 2020 | B2 |
| 11517656 | Joshi et al. | Dec 2022 | B2 |
| 20010000795 | Bolian, II et al. | May 2001 | A1 |
| 20010016985 | Insley et al. | Aug 2001 | A1 |
| 20010018308 | Quick et al. | Aug 2001 | A1 |
| 20010027302 | Glaug et al. | Oct 2001 | A1 |
| 20010027305 | Raidel et al. | Oct 2001 | A1 |
| 20010044610 | Kim et al. | Nov 2001 | A1 |
| 20010051178 | Blatchford et al. | Dec 2001 | A1 |
| 20010053904 | Abuto | Dec 2001 | A1 |
| 20020007167 | Dan et al. | Jan 2002 | A1 |
| 20020007169 | Graef et al. | Jan 2002 | A1 |
| 20020019602 | Geng | Feb 2002 | A1 |
| 20020019614 | Woon et al. | Feb 2002 | A1 |
| 20020026166 | Graef et al. | Feb 2002 | A1 |
| 20020034914 | De Leon et al. | Mar 2002 | A1 |
| 20020035354 | Mirle et al. | Mar 2002 | A1 |
| 20020062113 | Thomas et al. | May 2002 | A1 |
| 20020064639 | Rearick et al. | May 2002 | A1 |
| 20020087136 | Widlund | Jul 2002 | A1 |
| 20020090511 | Smith et al. | Jul 2002 | A1 |
| 20020110672 | Muratore-Pallatino et al. | Aug 2002 | A1 |
| 20020123728 | Graef et al. | Sep 2002 | A1 |
| 20020133132 | Copat et al. | Sep 2002 | A1 |
| 20020150678 | Cramer et al. | Oct 2002 | A1 |
| 20020165509 | Baer et al. | Nov 2002 | A1 |
| 20020169405 | Roberts | Nov 2002 | A1 |
| 20020176964 | Koslow | Nov 2002 | A1 |
| 20020177831 | Daley et al. | Nov 2002 | A1 |
| 20020180092 | Abba et al. | Dec 2002 | A1 |
| 20020183704 | Fields et al. | Dec 2002 | A1 |
| 20030009122 | Veras | Jan 2003 | A1 |
| 20030045707 | West et al. | Mar 2003 | A1 |
| 20030045825 | Etheredge, III | Mar 2003 | A1 |
| 20030050617 | Chen et al. | Mar 2003 | A1 |
| 20030069563 | Johnson | Apr 2003 | A1 |
| 20030070780 | Chen et al. | Apr 2003 | A1 |
| 20030073967 | Wahlstrom et al. | Apr 2003 | A1 |
| 20030088229 | Baker et al. | May 2003 | A1 |
| 20030088231 | Yoshimasa et al. | May 2003 | A1 |
| 20030093044 | Wahlstrom et al. | May 2003 | A1 |
| 20030097101 | Schmidt et al. | May 2003 | A1 |
| 20030097105 | Chen et al. | May 2003 | A1 |
| 20030097113 | Molee | May 2003 | A1 |
| 20030105442 | Johnston et al. | Jun 2003 | A1 |
| 20030114816 | Underhill et al. | Jun 2003 | A1 |
| 20030114818 | Benecke et al. | Jun 2003 | A1 |
| 20030114821 | Underhill et al. | Jun 2003 | A1 |
| 20030120249 | Wulz et al. | Jun 2003 | A1 |
| 20030121588 | Pargass et al. | Jul 2003 | A1 |
| 20030124311 | Cree et al. | Jul 2003 | A1 |
| 20030134559 | Delzer et al. | Jul 2003 | A1 |
| 20030135174 | Benecke et al. | Jul 2003 | A1 |
| 20030135177 | Baker | Jul 2003 | A1 |
| 20030150551 | Baker | Aug 2003 | A1 |
| 20030157857 | Cook et al. | Aug 2003 | A1 |
| 20030171729 | Kaun et al. | Sep 2003 | A1 |
| 20030180341 | Gooch et al. | Sep 2003 | A1 |
| 20030190854 | Stagray et al. | Oct 2003 | A1 |
| 20030199800 | Levin | Oct 2003 | A1 |
| 20030208175 | Gross et al. | Nov 2003 | A1 |
| 20030212359 | Butler | Nov 2003 | A1 |
| 20030225383 | Glaug et al. | Dec 2003 | A1 |
| 20040019338 | Litvay et al. | Jan 2004 | A1 |
| 20040019339 | Ranganathan et al. | Jan 2004 | A1 |
| 20040019340 | McBride | Jan 2004 | A1 |
| 20040019342 | Nagasuna et al. | Jan 2004 | A1 |
| 20040024102 | Hayes et al. | Feb 2004 | A1 |
| 20040024375 | Litvay | Feb 2004 | A1 |
| 20040033750 | Everett et al. | Feb 2004 | A1 |
| 20040049146 | Kolte et al. | Mar 2004 | A1 |
| 20040054343 | Barnett et al. | Mar 2004 | A1 |
| 20040054344 | Roettger et al. | Mar 2004 | A1 |
| 20040065420 | Graef et al. | Apr 2004 | A1 |
| 20040076662 | Riesinger | Apr 2004 | A1 |
| 20040078011 | Stevens | Apr 2004 | A1 |
| 20040078016 | Baker | Apr 2004 | A1 |
| 20040087927 | Suzuki | May 2004 | A1 |
| 20040106888 | Lutri et al. | Jun 2004 | A1 |
| 20040111074 | Eliasson | Jun 2004 | A1 |
| 20040127862 | Bubb et al. | Jul 2004 | A1 |
| 20040138602 | Rossen | Jul 2004 | A1 |
| 20040177935 | Hamed et al. | Sep 2004 | A1 |
| 20040181199 | Moberg-Alehammar et al. | Sep 2004 | A1 |
| 20040204696 | Chen | Oct 2004 | A1 |
| 20040230173 | Barge et al. | Nov 2004 | A1 |
| 20040230184 | Babusik et al. | Nov 2004 | A1 |
| 20040241214 | Kirkwood et al. | Dec 2004 | A1 |
| 20040243042 | Lipman | Dec 2004 | A1 |
| 20040243080 | Baer | Dec 2004 | A1 |
| 20040243081 | Suzuki et al. | Dec 2004 | A1 |
| 20040253894 | Fell et al. | Dec 2004 | A1 |
| 20040254552 | Mangold | Dec 2004 | A1 |
| 20050008825 | Casey et al. | Jan 2005 | A1 |
| 20050013992 | Azad et al. | Jan 2005 | A1 |
| 20050015036 | Lutri et al. | Jan 2005 | A1 |
| 20050049566 | Vukos et al. | Mar 2005 | A1 |
| 20050079361 | Hamed et al. | Apr 2005 | A1 |
| 20050096616 | Arora et al. | May 2005 | A1 |
| 20050112979 | Sawyer et al. | May 2005 | A1 |
| 20050119631 | Giloh et al. | Jun 2005 | A1 |
| 20050136773 | Yahiaoui et al. | Jun 2005 | A1 |
| 20050165371 | Giacometti | Jul 2005 | A1 |
| 20050215965 | Schmidt et al. | Sep 2005 | A1 |
| 20050215967 | Toro et al. | Sep 2005 | A1 |
| 20050222547 | Beruda et al. | Oct 2005 | A1 |
| 20050228353 | Thomas | Oct 2005 | A1 |
| 20050261649 | Cohen | Nov 2005 | A1 |
| 20050267429 | Cohen | Dec 2005 | A1 |
| 20060003604 | Angerpointner | Jan 2006 | A1 |
| 20060009744 | Erdman et al. | Jan 2006 | A1 |
| 20060020250 | Chester et al. | Jan 2006 | A1 |
| 20060058750 | Di Girolamo | Mar 2006 | A1 |
| 20060069366 | Cole | Mar 2006 | A1 |
| 20060069367 | Waksmundzki et al. | Mar 2006 | A1 |
| 20060069375 | Waksmundzki et al. | Mar 2006 | A1 |
| 20060122548 | Abrams | Jun 2006 | A1 |
| 20060122572 | Suarez | Jun 2006 | A1 |
| 20060153904 | Smith et al. | Jul 2006 | A1 |
| 20060161122 | Erdman et al. | Jul 2006 | A1 |
| 20060178650 | Hakansson et al. | Aug 2006 | A1 |
| 20060184147 | Hamed | Aug 2006 | A1 |
| 20060206047 | Lampe et al. | Sep 2006 | A1 |
| 20060206073 | Crane et al. | Sep 2006 | A1 |
| 20060206074 | Bernal et al. | Sep 2006 | A1 |
| 20060241542 | Gudnason et al. | Oct 2006 | A1 |
| 20060282028 | Howard et al. | Dec 2006 | A1 |
| 20070003604 | Jones | Jan 2007 | A1 |
| 20070021697 | Ginther et al. | Jan 2007 | A1 |
| 20070073254 | Ponomarenko et al. | Mar 2007 | A1 |
| 20070078467 | Mullen | Apr 2007 | A1 |
| 20070100308 | Miyairi | May 2007 | A1 |
| 20070142804 | Bernard | Jun 2007 | A1 |
| 20070167096 | Scott | Jul 2007 | A1 |
| 20070167884 | Mangrum et al. | Jul 2007 | A1 |
| 20070224903 | Chakravarty et al. | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070254550 | Hamed et al. | Nov 2007 | A1 |
| 20070270070 | Hamed | Nov 2007 | A1 |
| 20070282236 | LaGreca | Dec 2007 | A1 |
| 20080004581 | Babusik et al. | Jan 2008 | A1 |
| 20080015532 | Waksmundzki | Jan 2008 | A1 |
| 20080058691 | Sorensen | Mar 2008 | A1 |
| 20080058692 | Propp et al. | Mar 2008 | A1 |
| 20080082075 | Morrell-Schwartz | Apr 2008 | A1 |
| 20080090050 | Seyler et al. | Apr 2008 | A1 |
| 20080091152 | Asherman | Apr 2008 | A1 |
| 20080114317 | Seyler | May 2008 | A1 |
| 20080119586 | Byerly et al. | May 2008 | A1 |
| 20080147024 | Potts et al. | Jun 2008 | A1 |
| 20080167592 | Greer | Jul 2008 | A1 |
| 20080243100 | Wu et al. | Oct 2008 | A1 |
| 20080254103 | Harris et al. | Oct 2008 | A1 |
| 20080255533 | Wu et al. | Oct 2008 | A1 |
| 20080275409 | Kane et al. | Nov 2008 | A1 |
| 20080312621 | Hundorf et al. | Dec 2008 | A1 |
| 20080312622 | Hundorf et al. | Dec 2008 | A1 |
| 20090062760 | Wright et al. | Mar 2009 | A1 |
| 20090065014 | Nagata | Mar 2009 | A1 |
| 20090076472 | Goldwasser et al. | Mar 2009 | A1 |
| 20090112175 | Bissah et al. | Apr 2009 | A1 |
| 20090204087 | Herfert et al. | Aug 2009 | A1 |
| 20090216168 | Eckstein | Aug 2009 | A1 |
| 20090227935 | Zanella et al. | Sep 2009 | A1 |
| 20090227969 | Jaeb et al. | Sep 2009 | A1 |
| 20090240218 | Braga et al. | Sep 2009 | A1 |
| 20090281471 | Iwahashi et al. | Nov 2009 | A1 |
| 20090293887 | Wilkes et al. | Dec 2009 | A1 |
| 20090299251 | Buan | Dec 2009 | A1 |
| 20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
| 20090299340 | Kazala, Jr. et al. | Dec 2009 | A1 |
| 20100010461 | Herfert et al. | Jan 2010 | A1 |
| 20100010462 | Kurata | Jan 2010 | A1 |
| 20100030171 | Canada et al. | Feb 2010 | A1 |
| 20100036334 | Heagle et al. | Feb 2010 | A1 |
| 20100036342 | Carlucci et al. | Feb 2010 | A1 |
| 20100048072 | Kauschke et al. | Feb 2010 | A1 |
| 20100055158 | Vitaris et al. | Mar 2010 | A1 |
| 20100069858 | Olson | Mar 2010 | A1 |
| 20100084074 | McClernon et al. | Apr 2010 | A1 |
| 20100087767 | McNeil | Apr 2010 | A1 |
| 20100106120 | Holm | Apr 2010 | A1 |
| 20100106121 | Holm | Apr 2010 | A1 |
| 20100121286 | Locke et al. | May 2010 | A1 |
| 20100121298 | Seyler et al. | May 2010 | A1 |
| 20100122417 | Vrzalik et al. | May 2010 | A1 |
| 20100125234 | Smith | May 2010 | A1 |
| 20100125258 | Coulthard et al. | May 2010 | A1 |
| 20100168695 | Robles et al. | Jul 2010 | A1 |
| 20100179463 | Greener et al. | Jul 2010 | A1 |
| 20100217177 | Cali et al. | Aug 2010 | A1 |
| 20100256545 | Aali et al. | Oct 2010 | A1 |
| 20100256584 | Litvay | Oct 2010 | A1 |
| 20100256586 | Bergstrom et al. | Oct 2010 | A1 |
| 20100262091 | Larsson | Oct 2010 | A1 |
| 20100305526 | Robinson et al. | Dec 2010 | A1 |
| 20100318047 | Ducker et al. | Dec 2010 | A1 |
| 20100318052 | Ha et al. | Dec 2010 | A1 |
| 20100324516 | Braga et al. | Dec 2010 | A1 |
| 20110004172 | Eckstein et al. | Jan 2011 | A1 |
| 20110052664 | Tennican et al. | Mar 2011 | A1 |
| 20110054422 | Locke et al. | Mar 2011 | A1 |
| 20110059329 | Dobrawa et al. | Mar 2011 | A1 |
| 20110060303 | Bissah et al. | Mar 2011 | A1 |
| 20110092927 | Wilkes et al. | Apr 2011 | A1 |
| 20110098621 | Fabo et al. | Apr 2011 | A1 |
| 20110106030 | Scholz | May 2011 | A1 |
| 20110112492 | Bharti et al. | May 2011 | A1 |
| 20110125119 | Weismantel et al. | May 2011 | A1 |
| 20110137222 | Masini | Jun 2011 | A1 |
| 20110152813 | Ellingson | Jun 2011 | A1 |
| 20110178375 | Forster | Jul 2011 | A1 |
| 20110183109 | Seyler et al. | Jul 2011 | A1 |
| 20110184364 | Biggs et al. | Jul 2011 | A1 |
| 20110184370 | Seyler et al. | Jul 2011 | A1 |
| 20110208145 | Zhang et al. | Aug 2011 | A1 |
| 20110213286 | Riesinger | Sep 2011 | A1 |
| 20110218509 | Dontas | Sep 2011 | A1 |
| 20110223413 | Herfert et al. | Sep 2011 | A1 |
| 20110224631 | Simmons et al. | Sep 2011 | A1 |
| 20110238026 | Zhang et al. | Sep 2011 | A1 |
| 20110245788 | Marquez | Oct 2011 | A1 |
| 20110247636 | Pollack | Oct 2011 | A1 |
| 20110257572 | Locke et al. | Oct 2011 | A1 |
| 20110268932 | Catalan et al. | Nov 2011 | A1 |
| 20120004632 | Zhang et al. | Jan 2012 | A1 |
| 20120045639 | Whitmore et al. | Feb 2012 | A1 |
| 20120053547 | Schroeder et al. | Mar 2012 | A1 |
| 20120071848 | Zhang et al. | Mar 2012 | A1 |
| 20120095426 | Visscher et al. | Apr 2012 | A1 |
| 20120101465 | McGuire, Jr. | Apr 2012 | A1 |
| 20120123311 | Weidemann-Hendrickson et al. | May 2012 | A1 |
| 20120130332 | Cotton et al. | May 2012 | A1 |
| 20120136329 | Carney | May 2012 | A1 |
| 20120143158 | Yang et al. | Jun 2012 | A1 |
| 20120172778 | Rastegar et al. | Jul 2012 | A1 |
| 20120197229 | Buan et al. | Aug 2012 | A1 |
| 20120203145 | Nilsson | Aug 2012 | A1 |
| 20120203189 | Barta et al. | Aug 2012 | A1 |
| 20120220968 | Confalone et al. | Aug 2012 | A1 |
| 20120232502 | Lowing | Sep 2012 | A1 |
| 20120238932 | Atteia et al. | Sep 2012 | A1 |
| 20120283529 | Marchand et al. | Nov 2012 | A1 |
| 20120302440 | Theliander et al. | Nov 2012 | A1 |
| 20120308780 | Rottger et al. | Dec 2012 | A1 |
| 20120310186 | Moghe et al. | Dec 2012 | A1 |
| 20120310197 | Thomas | Dec 2012 | A1 |
| 20120330252 | Stokes et al. | Dec 2012 | A1 |
| 20120330253 | Robinson et al. | Dec 2012 | A1 |
| 20130012902 | Rovaniemi | Jan 2013 | A1 |
| 20130150814 | Buan | Jun 2013 | A1 |
| 20140114268 | Auguste et al. | Apr 2014 | A1 |
| 20150159066 | Hartwell et al. | Jun 2015 | A1 |
| 20150174304 | Askem et al. | Jun 2015 | A1 |
| 20180021178 | Locke et al. | Jan 2018 | A1 |
| 20180125720 | Pigg | May 2018 | A1 |
| 20180369462 | Anderson et al. | Dec 2018 | A1 |
| 20190110932 | Mumby et al. | Apr 2019 | A1 |
| 20190216651 | Vitaris et al. | Jul 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 101002707 | Jul 2007 | CN |
| 0053936 | Jun 1982 | EP |
| 0147119 | Jul 1985 | EP |
| 0541251 | May 1993 | EP |
| 0619105 | Oct 1994 | EP |
| 0549781 | Sep 1996 | EP |
| 0748894 | Dec 1996 | EP |
| 0599871 | Apr 1997 | EP |
| 0875224 | Nov 1998 | EP |
| 0941726 | Sep 1999 | EP |
| 1013290 | Jun 2000 | EP |
| 1048278 | Nov 2000 | EP |
| 1066809 | Jan 2001 | EP |
| 1139951 | Oct 2001 | EP |
| 1312328 | May 2003 | EP |
| 1452156 | Sep 2004 | EP |
| 2161011 | Mar 2010 | EP |
| 2263627 | Dec 2010 | EP |
| 2366721 | Sep 2011 | EP |
| 2529767 | Dec 2012 | EP |
| 2659915 | Oct 2015 | EP |
| 2272917 | Jun 1994 | GB |
| 2355228 | Apr 2001 | GB |
| 2435422 | Aug 2007 | GB |
| 2435423 | Aug 2007 | GB |
| 2489947 | Oct 2012 | GB |
| S57119738 | Jul 1982 | JP |
| 2001145655 | May 2001 | JP |
| 2007275185 | Oct 2007 | JP |
| 2008119497 | May 2008 | JP |
| WO-9111161 | Aug 1991 | WO |
| WO-9111162 | Aug 1991 | WO |
| WO-9301778 | Feb 1993 | WO |
| WO-9301779 | Feb 1993 | WO |
| WO-9301780 | Feb 1993 | WO |
| WO-9301781 | Feb 1993 | WO |
| WO-9309745 | May 1993 | WO |
| WO-9311726 | Jun 1993 | WO |
| WO-9513042 | May 1995 | WO |
| WO-9513776 | May 1995 | WO |
| WO-9513779 | May 1995 | WO |
| WO-9514451 | Jun 1995 | WO |
| WO-9516424 | Jun 1995 | WO |
| WO-9607783 | Mar 1996 | WO |
| WO-9621410 | Jul 1996 | WO |
| WO-9711658 | Apr 1997 | WO |
| WO-9714384 | Apr 1997 | WO |
| WO-9820916 | May 1998 | WO |
| WO-9822279 | May 1998 | WO |
| WO-9904830 | Feb 1999 | WO |
| WO-9939671 | Aug 1999 | WO |
| WO-9945876 | Sep 1999 | WO |
| WO-9945878 | Sep 1999 | WO |
| WO-9956687 | Nov 1999 | WO |
| WO-0000016 | Jan 2000 | WO |
| WO-0000127 | Jan 2000 | WO |
| WO-0000129 | Jan 2000 | WO |
| WO-0000130 | Jan 2000 | WO |
| WO-0000131 | Jan 2000 | WO |
| WO-0040190 | Jul 2000 | WO |
| WO-0042957 | Jul 2000 | WO |
| WO-0059438 | Oct 2000 | WO |
| WO-0172251 | Oct 2001 | WO |
| WO-0190465 | Nov 2001 | WO |
| WO-0217840 | Mar 2002 | WO |
| WO-0224132 | Mar 2002 | WO |
| WO-0226180 | Apr 2002 | WO |
| WO-0238096 | May 2002 | WO |
| WO-02076379 | Oct 2002 | WO |
| WO-02089719 | Nov 2002 | WO |
| WO-03057307 | Jul 2003 | WO |
| WO-03073971 | Sep 2003 | WO |
| WO-2004043321 | May 2004 | WO |
| WO-2004073566 | Sep 2004 | WO |
| WO-2004098474 | Nov 2004 | WO |
| WO-2006105305 | Oct 2006 | WO |
| WO-2007035038 | Mar 2007 | WO |
| WO-2007040606 | Apr 2007 | WO |
| WO-2007077214 | Jul 2007 | WO |
| WO-2007077216 | Jul 2007 | WO |
| WO-2007082538 | Jul 2007 | WO |
| WO-2007116347 | Oct 2007 | WO |
| WO-2007134516 | Nov 2007 | WO |
| WO-2008013896 | Jan 2008 | WO |
| WO-2008049277 | May 2008 | WO |
| WO-2008131895 | Nov 2008 | WO |
| WO-2009019227 | Feb 2009 | WO |
| WO-2009019229 | Feb 2009 | WO |
| WO-2009066104 | May 2009 | WO |
| WO-2009066105 | May 2009 | WO |
| WO-2009066106 | May 2009 | WO |
| WO-2009103031 | Aug 2009 | WO |
| WO-2009146441 | Dec 2009 | WO |
| WO-2009152021 | Dec 2009 | WO |
| WO-2010032951 | Mar 2010 | WO |
| WO-2010072395 | Jul 2010 | WO |
| WO-2010082872 | Jul 2010 | WO |
| WO-2010089448 | Aug 2010 | WO |
| WO-2010139926 | Dec 2010 | WO |
| WO-2011019476 | Feb 2011 | WO |
| WO-2011023275 | Mar 2011 | WO |
| WO-2011023650 | Mar 2011 | WO |
| WO-2011057240 | May 2011 | WO |
| WO-2011058311 | May 2011 | WO |
| WO-2011063818 | Jun 2011 | WO |
| WO-2011080427 | Jul 2011 | WO |
| WO-2011113728 | Sep 2011 | WO |
| WO-2011115908 | Sep 2011 | WO |
| WO-2011128651 | Oct 2011 | WO |
| WO-2011135284 | Nov 2011 | WO |
| WO-2011152368 | Dec 2011 | WO |
| WO-2012009370 | Jan 2012 | WO |
| WO-2012035787 | Mar 2012 | WO |
| WO-2012074512 | Jun 2012 | WO |
| WO-2012146656 | Nov 2012 | WO |
| WO-2012150235 | Nov 2012 | WO |
| WO-2012168298 | Dec 2012 | WO |
| WO-2013014317 | Jan 2013 | WO |
| WO-2013029652 | Mar 2013 | WO |
| WO-2013060732 | May 2013 | WO |
| WO-2013136181 | Sep 2013 | WO |
| WO-2013175306 | Nov 2013 | WO |
| WO-2014003957 | Jan 2014 | WO |
| 9605526 | Feb 1997 | ZA |
| Entry |
|---|
| International Preliminary Report on Patentability for Application No. PCT/EP2017/077154, mailed on May 9, 2019, 8 pages. |
| International Search Report and Written Opinion for Application No. PCT/EP2017/077154, mailed on Dec. 1, 2017, 10 pages. |
| Brief Communication—Letter from the Opponent of the Patent dated Oct. 12, 2020, for withdraw the Opposition of European Patent No. EP2731564, 4 pages. |
| Brief Communication—Letter from the Proprietor of the Patent dated Jun. 16, 2020, for the Opposition of European Patent No. EP2731564, 19 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2012/000587, mailed on Jan. 23, 2014, 12 pages. |
| International Search Report and Written Opinion for Application No. PCT/GB2012/000587, mailed on Oct. 8, 2013, 17 pages. |
| KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390061 Rev D, Jan. 2010, 10 pages. |
| KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390153-WEB Rev B, Jan. 2010, 12 pages. |
| KCI Licensing, “Prevena™ Incision Management System—Patient Guide”, 390064 Rev D, Jan. 2010, 4 pages. |
| KCI Licensing, “Prevena™ Incision Management System—Patient Guide,” 390152-WEB C, Jan. 2011, 6 pages. |
| KCI Licensing, Prevena™ Incision Management System, Jun. 22, 2010, in 2 pages. |
| Notice of Opposition—Statement of Facts and Evidence for the European Patent No. 2731564, mailed on Jan. 22, 2020, 12 pages. |
| Smith & Nephew, Allevyn Gentle Border Multisite, Jun. 2011, 2 pages. |
| Smith and Nephew Inc., “Allevyn Wound Dressings Pamphlet,” 2008, 2 pages. |
| Termination of the Opposition Proceedings with Maintenance of the Patent for European Patent No. 2731564, dated Apr. 1, 2021, 1 page. |
| Number | Date | Country | |
|---|---|---|---|
| 20220183894 A1 | Jun 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16195186 | Nov 2018 | US |
| Child | 17563925 | US | |
| Parent | 15219886 | Jul 2016 | US |
| Child | 16195186 | US | |
| Parent | 14232607 | US | |
| Child | 15219886 | US |
